Skip to main content

Table 1 Basic information of extracted patients from SEER diagnosed in 2010–2015

From: Comparison of metastasis between early-onset and late-onset gastric signet ring cell carcinoma

Variables Total Early-onset SRCC Late-onset SRCC P value
Total 2052 234 1818  
Sex     0.0005
Male 1034 (50.39%) 94 (40.17%) 949 (52.2%)  
Female 1009 (49.61%) 140 (59.83%) 869 (47.8%)  
Race     0.739
White 1381 (67.3%) 157 (67.1%) 1224 (67.33%)  
Black 252 (12.28%) 32 (13.67%) 220 (12.1%)  
Other 419 (20.42%) 45 (19.23%) 374 (20.57%  
Primary site     0.013
Cardia 283 (13.79%) 20 (8.55%) 263 (14.47%)  
Fundus 54 (2.63%) 7 (2.99%) 47 (2.59%)  
Antrum 1076 (52.44%) 118 (50.43%) 958 (52.7%)  
Body 232 (11.31%) 39 (16.67%) 193 (10.6%)  
Overlappping/NOS 407 (18.83%) 50 (21.37%) 357 (19.64%)  
T stage     0.657
Tis/T1 408 (19.88%) 45 (19.23%) 363 (19.97%)  
T2 224 (10.92%) 30 (12.82%) 194 (10.67%)  
T3 694 (33.82%) 73 (31.2%) 621 (34.16%)  
T4 726 (35.38%) 86 (36.75%) 640 (35.2%)  
N stage     0.738
N0 731 (35.62%) 86 (36.75%) 645 (35.48%)  
N1 357 (17.4%) 37 (15.81%) 320 (17.6%)  
N2 346 (16.86%) 44 (18.8%) 302 (16.61%)  
N3 638 (31.09%) 67 (28.63%) 551 (30.3%)  
M stage     0.000
M0 1818 (88.6% 188 (80.34%) 1630 (89.66%)  
M1 234 (11.4%) 46 (19.66%) 188 (10.34%)  
Tumor number     0.000
1 1629 (79.39%) 217 (92.74%) 1412 (77.67%)  
 > 1 423 (20.61%) 17 (7.26%) 406 (22.33%)  
Tumor size     0.99
 ≤ 2 cm 430 (20.96%) 51 (21.79%) 389 (21.4%)  
≤ 5 cm 793 (38.65%) 90 (38.46%) 703 (38.67%)  
 > 5 cm 819 (39.91%0 93 (39.74%) 726 (39.93%)  
Examined LNs     0.227
≤ 16 997 (48.59%) 105 (44.87%) 892 (49.06%)  
 > 16 1055 (51.41%) 129 (55.13%) 926 (50.94%)  
Chemotherapy     0.000
No 1295 (63.11%) 90 (38.46%) 1205 (66.28%)  
Yes 757 (36.89%) 144 (61.54%) 613 (33.72%)  
\